Sutro Biopharma, Inc.
STRO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $62 | $154 | $68 | $62 |
| % Growth | -59.6% | 126.8% | 9.5% | – |
| Cost of Goods Sold | $7 | $7 | $8 | $10 |
| Gross Profit | $55 | $147 | $59 | $52 |
| % Margin | 88.4% | 95.6% | 87.8% | 84.2% |
| R&D Expenses | $252 | $180 | $137 | $104 |
| G&A Expenses | $48 | $63 | $60 | $56 |
| SG&A Expenses | $48 | $63 | $60 | $56 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$7 | -$7 | -$8 | -$10 |
| Operating Expenses | $293 | $236 | $188 | $151 |
| Operating Income | -$238 | -$89 | -$129 | -$99 |
| % Margin | -384.3% | -58.1% | -190.3% | -159.2% |
| Other Income/Exp. Net | $13 | $1 | $12 | -$7 |
| Pre-Tax Income | -$225 | -$89 | -$117 | -$106 |
| Tax Expense | $2 | $18 | $3 | $0 |
| Net Income | -$227 | -$107 | -$119 | -$106 |
| % Margin | -366.6% | -69.5% | -175.9% | -170.6% |
| EPS | -29.6 | -17.8 | -23.5 | -22.9 |
| % Growth | -66.3% | 24.3% | -2.6% | – |
| EPS Diluted | -29.6 | -17.8 | -23.5 | -22.9 |
| Weighted Avg Shares Out | 8 | 6 | 5 | 5 |
| Weighted Avg Shares Out Dil | 8 | 6 | 5 | 5 |
| Supplemental Information | – | – | – | – |
| Interest Income | $44 | $15 | $3 | $1 |
| Interest Expense | $31 | $24 | $3 | $3 |
| Depreciation & Amortization | $7 | $7 | $8 | $5 |
| EBITDA | -$180 | -$68 | -$105 | -$98 |
| % Margin | -290.9% | -44.2% | -155% | -157.7% |